Phase II Randomized Trial of SLOG vs GC in Locally Advanced or Metastatic Biliary Tract Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the following items in patients with locally advanced and metastatic biliary
tract cancer receiving SLOG or GC treatment, Primary objective: 6-month progression-free
survival rate
Secondary objectives:
Objective response rate Disease control rate (Objective response rate (ORR) + stable disease
≧ 12 weeks) Progression-free Survival Overall survival Safety profile Biomarker study